B. Froissart

Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, JHEP reports : innovation in hepatology.

c-Ha-ras polymorphism in patients with hepatocellular carcinoma. Comparison of healthy subjects and alcoholic patients with cirrhosis.

J. Seigneurin, J. Zarski, M. Thelu, 1993, Gastroenterologie clinique et biologique.

Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

M. Chevallier, T. Fontanges, C. Trépo, 2008, Gastroenterologie clinique et biologique.

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, Journal of Cannabis Research.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

V. de Lédinghen, T. Asselah, D. Thabut, 2021, BMC Infectious Diseases.

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.